$2.67-0.14 (-4.98%)
BIO-key International, Inc.
BIO-key International, Inc. in the Industrials sector is trading at $2.67 with a market capitalization of $4M. Wall Street consensus targets $20.00 (1 analysts), implying a +649.1% move over the next 12 months. The stock is currently near its 52-week low of $2.65, remaining 50.6% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 30 is oversold, raising the odds of a near-term bounce. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.92Mβ | $2.15Mβ | $1.08Mβ | $1.55Mβ | $1.70M |
| Gross Profit | $1.67Mβ | $1.77Mβ | $812,412β | $1.19Mβ | $1.23M |
| Operating Income | -$529,405β | -$157,713β | -$1.71Mβ | -$892,190β | -$1.08M |
| Net Income | -$576,852β | -$205,037β | -$4.29Mβ | -$964,849β | -$1.17M |
BIO-key International, Inc. develops and markets fingerprint identification biometric technology and software solutions, and enterprise-ready identity access management solutions in the United States and internationally. It offers BIO-key PortalGuard...

License fees surged 53% as net loss improved 51% year over year.
BIO-key International Inc (BKYI) boosts gross margins to 87% on strong license growth, while a delayed hardware order shifts key revenue to the second half.

Moby summary of BIO-key International, Inc.'s Q2 2026 earnings call
Moby summary of BIO-key International, Inc.'s Q1 2026 earnings call
BIO-key International Inc (BKYI) reports a 34% revenue increase and improved net loss, while navigating NASDAQ suspension and expanding its market reach through strategic partnerships.